Your browser doesn't support javascript.
loading
The new paradigm of systemic therapies for metastatic melanoma.
Volpe, Virginia O; Klufas, Daniel M; Hegde, Upendra; Grant-Kels, Jane M.
Afiliação
  • Volpe VO; Department of Internal Medicine, Division of Oncology's Neag Cancer Center, University of Connecticut Health Center, Farmington, Connecticut.
  • Klufas DM; Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut.
  • Hegde U; Department of Internal Medicine, Division of Oncology's Neag Cancer Center, University of Connecticut Health Center, Farmington, Connecticut.
  • Grant-Kels JM; Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut. Electronic address: grant@uchc.edu.
J Am Acad Dermatol ; 77(2): 356-368, 2017 Aug.
Article em En | MEDLINE | ID: mdl-28711086
New treatments for metastatic melanoma work through distinct mechanisms: enhancing the immune response and blocking cellular proliferation. Agents that enhance the immune response include ipilimumab, pembrolizumb, and nivolumab; agents that block cellular proliferation include vemurafenib, dabrafenib, trametinib, cobimetinib, binimetinib, and selumetinib. The translational impact of laboratory discoveries has revolutionized management of metastatic melanoma and enhanced the prognosis of affected patients.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Inibidores de Proteínas Quinases / Fatores Imunológicos / Melanoma / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Inibidores de Proteínas Quinases / Fatores Imunológicos / Melanoma / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2017 Tipo de documento: Article